OncLive Insights

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, provide comprehensive insights on the evolving treatment landscape for patients with HR+ breast cancer and ESR1 mutations.

A panel of oncology specialists explores the latest developments in HER2-directed ADCs for solid tumors, emphasizing the growing potential in gynecological cancers.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements made in treatment approaches for NSCLC in 2023.

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

Expert medical oncologists Laura Spring, MD, and Manali Bhave, MD, discuss recent advances in the treatment of HER2-positive and HER2-low breast cancer, present hypothetical patient cases, and discuss their treatment approaches to illustrate how to incorporate recent data into practice.

Experts Joyce O’Shaughnessy, MD, and Erin Cobain, MD, review the clinical evolution of treatments in early-stage breast cancers, highlighting the latest data in genomic testing presented at the SABCS 2023 annual congress.

A panel of three, renowned oncologists discuss the evolving landscape of CAR-T cell therapies for adult patients with relapsed or refractory acute lymphoblastic leukemia after receiving two or more lines of prior therapy.

A group of oncology experts discusses the adjuvant treatment of melanoma, providing expert insights into the management of immunotherapy-related endocrine and cardiac toxicities, with a case discussion to emphasize these important topics.

Patient and provider perspectives are shared regarding available treatments, as well as how to manage treatment-related adverse events that can effect the quality of life for a patient diagnosed with cholangiocarcinoma.

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

A team of oncology experts discuss how collaboration among healthcare professionals can optimize care and improve quality of life for patients with advanced stage prostate cancer.

Neal Shore, MD, FACS, and Rana McKay, MD, discuss recent advances in understanding and targeting androgen receptor signaling in metastatic prostate cancer and emerging treatment approaches.

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements in immunotherapy-based treatment approaches for NSCLC in 2023.

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs).

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

Expert Nicole Lamanna, MD, reviews the clinical evolution of targeted therapies in in B-cell malignancies, highlighting the latest data in CLL to be presented at the upcoming ASH 2023 annual congress.

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.

Expert oncologists reflect on the evolving treatment paradigm for KRAS-mutated metastatic NSCLC with insight into data from ESMO 2023 and surrounding meetings, discussing targeted therapies and future perspectives in clinical practice.

Experts explore the transformative impact of CAR T-cell therapy on lymphoma treatment, covering mechanisms of action, first-line applications, and ongoing challenges.

Expert oncologists discuss the role of molecular genotyping in metastatic nonsquamous NSCLC in the context of of latest clinical research and consider its impact on treatment selection.

Discover the latest advancements and challenges in the treatment of endometrial cancer, from therapeutic breakthroughs to the importance of diverse clinical trial enrollment, presented by leading experts in gynecologic oncology.

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss the treatment landscape for patients with advanced non–small cell lung cancer and the emerging role of targeting HER3.

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

A panel of experts discusses the current landscape of multi-cancer early detection, addressing its potential to broaden access and improve cancer screening, emphasizing the importance of clinical trials and equitable healthcare distribution.

A panel of experts in the field of lower-risk myelodysplastic syndrome discusses current treatment paradigms, reviews clinical trial data, and provides insight on the evolving treatment landscape.

Ramez Eskander, MD, and Krishnansu Tewari, MD, discuss the evolving treatment landscape in the management of advanced or recurrent endometrial cancer.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, discuss their approaches to the treatment and management of patients with HR-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC) in clinical practice.

Expert physicians delve into the latest data and strategies for managing newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Expert oncologists review data presented at recent conferences and discuss current multidisciplinary strategies for the treatment of patients with HR+/HER2- breast cancer.

John Mascarenhas, MD, and Joe Scandura, MD, PhD, discuss recent advances in the treatment of polycythemia vera (PV) and the impact on clinical practice.

A multidisciplinary team from Dana-Farber Cancer Institute discusses their approach to the care of patients with graft versus host disease.